Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a Nov. 10, 2009, District Court decision that the Company’s generic version of Takeda’s Prevacid® (lansoprazole) SoluTab does not infringe U.S. Patent No. 5,464,632.

Teva’s Abbreviated New Drug Application (ANDA) to market lansoprazole orally disintegrating tablets is currently pending final approval at the U.S. Food and Drug Administration (FDA).

Annual sales of the brand product were approximately $513 million in the United States based on IMS sales data.

Source
Teva Pharmaceutical Industries Ltd.